Capricor Therapeutics Incorporated will face an advisory committee of the United States Food and Drug Administration on July 29, 2026, as regulators assess whether deramiocel should become the first approved cell therapy designed to preserve both skeletal and cardiac muscle function in Duchenne muscular dystrophy.
The meeting arrives less than one month before the FDA’s August 22 target decision date and represents the most important regulatory test in Capricor’s history. Deramiocel has moved from a complete response letter in July 2025 to a renewed application supported by the positive Phase 3 HOPE-3 study, which met its primary upper-limb endpoint and a key cardiac endpoint.
Capricor has also reported five-year follow-up from a small open-label extension in which remaining patients experienced slower upper-limb decline and stable cardiac function relative to external comparator models.
The total evidence is substantially stronger than the package rejected in 2025. However, the advisory committee will still need to determine whether the size and durability of the treatment effect justify approval, how much confidence should be placed in the long-term external comparisons and whether the company can manufacture and commercialise a living-cell product consistently.
Why is the July 29 FDA advisory committee more than a routine step for Capricor?
FDA advisory committees are convened when regulators want external experts to examine scientific, clinical or safety questions before making a decision. The panel’s recommendation is not legally binding, but it can shape the agency’s final assessment and influence physician, payer and investor confidence.
For Capricor, the meeting will revisit a therapy that the FDA declined to approve in July 2025. The original application relied primarily on the Phase 2 HOPE-2 trial, its open-label extension and comparisons with natural-history datasets.
The FDA concluded at that time that the evidence did not meet the required effectiveness standard. It also said it had been unable to complete the review of parts of the chemistry, manufacturing and controls package.
Capricor subsequently incorporated results from the randomised Phase 3 HOPE-3 trial into a Class 2 resubmission. The FDA resumed its review in March 2026 and established the August 22 action date.
The advisory committee therefore will not be evaluating the same evidence that was rejected a year earlier. HOPE-3 provides a larger, placebo-controlled dataset that directly addresses the central weakness of the earlier application.
The decision to hold a public panel nevertheless indicates that important questions remain. The FDA could seek advice on the clinical meaningfulness of the upper-limb benefit, the interpretation of cardiac imaging, the target population, treatment duration, safety or the consistency of manufacturing.
How much stronger is the deramiocel application after the Phase 3 HOPE-3 trial?
HOPE-3 enrolled 106 boys and young men with Duchenne muscular dystrophy across 20 clinical sites in the United States. The average participant was approximately 15 years old, and all patients remained on a stable corticosteroid regimen.
Participants were randomly assigned to receive either 150 million deramiocel cells or placebo through an intravenous infusion every three months for one year.
The trial met its primary endpoint on the Performance of the Upper Limb 2.0 scale. Capricor reported that deramiocel slowed deterioration by approximately 54% compared with placebo, with a p-value of 0.029.
The study also met its key cardiac endpoint. Decline in left ventricular ejection fraction was slowed by approximately 91%, with a p-value of 0.041.
Approximately three-quarters of participants had a clinical diagnosis of cardiomyopathy at enrolment, and around 90% were already receiving cardiac medication. This makes the heart result particularly relevant because it was observed on top of existing supportive treatment rather than in an untreated population.
Capricor also reported success across all other secondary endpoints protected by the trial’s statistical hierarchy. These included imaging and functional measures intended to assess cardiac fibrosis, upper-limb ability and activities of daily living.
The randomised design is the most important change in the regulatory case. The company no longer needs to depend primarily on comparisons with historical patients to argue that deramiocel modifies the course of Duchenne muscular dystrophy.
Why does preserving upper-limb function matter after patients lose the ability to walk?
Duchenne muscular dystrophy is caused by mutations that prevent the body from producing functional dystrophin, a protein needed to protect skeletal and cardiac muscle cells.
Muscle weakness generally begins in early childhood and progressively affects walking, standing and climbing. Many patients eventually become dependent on wheelchairs, but disease progression does not stop when ambulation is lost.
Weakness spreads into the shoulders, arms and hands. Patients may gradually lose the ability to feed themselves, operate a wheelchair, use a phone, perform personal care or reposition their bodies independently.
The Performance of the Upper Limb scale measures abilities that remain important to patients long after walking endpoints become unusable. Preserving several points on the scale can translate into maintaining daily activities for longer.
HOPE-3’s average age and disease profile allowed Capricor to study a population with significant existing weakness. This is commercially and clinically relevant because many mutation-specific therapies and earlier-stage development programmes focus primarily on younger ambulatory children.
Deramiocel could potentially provide an option for a broader population because its mechanism is not designed to correct one particular dystrophin mutation.
The committee must still decide whether the average treatment difference is large enough to represent a meaningful benefit for individual patients. Statistical significance confirms that the groups differed, but clinical significance depends on which abilities were preserved and how consistently patients experienced that benefit.
Could deramiocel become the first Duchenne therapy to address both skeletal and cardiac decline?
Many Duchenne development programmes focus on restoring dystrophin, altering RNA processing or improving skeletal muscle function. Cardiac disease can remain difficult to treat because delivery to heart tissue and measurement of clinical benefit create additional challenges.
Cardiomyopathy develops as cardiac muscle is repeatedly damaged and replaced by fibrotic tissue. As the heart becomes weaker, patients face arrhythmias, reduced pumping capacity and heart failure.
Deramiocel is designed to influence both skeletal and cardiac muscle through an immunomodulatory and anti-fibrotic mechanism. The product consists of allogeneic cardiosphere-derived cells obtained from donor heart tissue.
These cells are not intended to replace damaged muscle directly or insert a functioning dystrophin gene. They release extracellular vesicles and other biological signals that may reduce harmful inflammation and fibrosis while encouraging a more reparative immune environment.
This approach could make deramiocel complementary to mutation-specific and gene-based treatments. A patient might receive a therapy aimed at the genetic cause while deramiocel addresses downstream inflammation and tissue damage.
That possibility is scientifically attractive but has not been established through formal combination studies. The FDA will evaluate deramiocel according to the evidence in its submitted population, not according to hypothetical future use with other therapies.
Do the five-year HOPE-2 extension results prove that the benefit remains durable?
Capricor’s latest long-term analysis includes nine patients who remain in the HOPE-2 open-label extension.
Across five years, these patients experienced an average decline of less than five points on the Performance of the Upper Limb scale. This equates to approximately one point of decline per year.
Capricor compared the result with a matched external cohort that showed a modelled decline of roughly 2.4 points annually, which would project to approximately 12 points over five years. The company also referenced published natural-history research showing substantial upper-limb deterioration among non-ambulant patients over three years.
Cardiac function, measured through left ventricular ejection fraction on magnetic resonance imaging, remained broadly stable among the extension participants. The external cardiac comparison projected an annual decline of approximately 3.2%.
These findings support the possibility that repeated deramiocel infusions have a durable biological effect. The consistency between the long-term observation and the randomised Phase 3 results strengthens the overall narrative.
However, nine continuing patients represent a highly selected and very small group. People who remain in a five-year extension may differ from those who discontinue because of disease progression, logistical burdens or other factors.
External comparators also cannot balance every difference in age, disease severity, supportive care and treatment history. They provide context but remain less reliable than continued randomised follow-up.
The five-year results should therefore be viewed as supportive evidence of durability rather than independent proof of efficacy.
Why could the FDA focus closely on left ventricular ejection fraction and cardiac fibrosis?
The HOPE-3 cardiac endpoint measured left ventricular ejection fraction, which reflects the percentage of blood pumped from the heart’s main chamber during each contraction.
A slower decline suggests that cardiac pumping function is being preserved. In Duchenne muscular dystrophy, even modest preservation may matter because cardiomyopathy progresses over time and can become life-threatening.
Yet ejection fraction is influenced by measurement variability, loading conditions and the stage of cardiac disease. Regulators may ask whether the observed difference is consistent across patients and supported by additional cardiac measures.
Capricor has reported that cardiac magnetic resonance imaging showed reduced progression of myocardial fibrosis relative to placebo. Fibrosis is important because scar tissue accumulating within the heart is generally irreversible and can precede obvious deterioration in pumping function.
Agreement between ejection fraction and fibrosis measures would strengthen the conclusion that deramiocel is affecting the disease process rather than producing a temporary imaging fluctuation.
The panel may also examine whether the cardiac benefit is large enough to predict reduced heart failure, hospitalisation or mortality over a longer period.
HOPE-3 lasted one year, while major cardiac outcomes may take several years to emerge. Approval may therefore depend partly on accepting imaging and functional measures as evidence reasonably connected to future clinical benefit.
Can a donor-derived cell therapy be administered safely every three months for years?
Deramiocel is administered intravenously every three months. The programme has generated experience from more than 800 infusions, and Capricor says no new safety signal emerged from either HOPE-3 or the five-year extension.
Repeated use of an allogeneic cell product raises several theoretical risks, including infusion reactions, immune responses, infection and variability between manufactured batches.
The company’s reported safety profile has so far appeared manageable, but the advisory committee will review the complete incidence, severity and timing of adverse events rather than relying on summary descriptions.
Long-term safety is particularly important because patients may continue treatment for years. A therapy intended to slow progression rather than produce a one-time correction must maintain an acceptable risk profile across repeated dosing.
The absence of conditioning chemotherapy is a potential practical advantage. Deramiocel does not require patients to undergo the lymphodepletion used with some cellular therapies.
The product also avoids permanent genetic modification. Treatment can be discontinued if the risk-benefit balance changes, although benefits may diminish if dosing stops.
Regulators may request post-marketing studies or registries to monitor uncommon immune, cardiac and infusion-related complications if the therapy is approved.
Why does manufacturing remain a major regulatory issue for a living-cell product?
Manufacturing is not merely a commercial concern for cell therapy. It determines whether each patient receives a product with consistent identity, potency, purity and biological activity.
Deramiocel is manufactured from donor-derived cardiosphere cells. Capricor must demonstrate that different production lots perform consistently despite natural biological variation in the starting material.
The company operates its own good manufacturing practice facility and has been expanding capacity in preparation for a possible launch.
This gives Capricor greater control over production, but it also makes the company directly responsible for scaling a complex manufacturing process from clinical trials into commercial supply.
The FDA’s 2025 complete response letter indicated that the agency had not completed its review of parts of the chemistry, manufacturing and controls package. Capricor later submitted additional information and has said it responded to a significant number of agency requests during the resumed review.
The advisory committee may concentrate primarily on clinical evidence, while manufacturing questions remain within the FDA’s internal review. Approval still depends on both elements being resolved.
A positive panel vote cannot compensate for unresolved facility, process-validation or product-consistency concerns.
Could the FDA approve a broader Duchenne label than the original cardiomyopathy application?
The original application was described primarily as seeking approval for cardiomyopathy associated with Duchenne muscular dystrophy.
Following the HOPE-3 results, Capricor has increasingly described the resubmitted application as seeking approval for the treatment of Duchenne muscular dystrophy, highlighting both skeletal and cardiac benefits.
This creates an important label question. HOPE-3 enrolled ambulatory and non-ambulatory patients with substantial upper-limb and cardiac involvement. The FDA must determine which ages, functional stages and disease characteristics are adequately represented by the evidence.
A broad label could position deramiocel as a disease-modifying therapy across a sizeable portion of the Duchenne population. A narrower label might limit initial use to older patients, those with cardiomyopathy or patients meeting specific functional criteria.
The advisory committee briefing materials should reveal whether the agency views the skeletal endpoint as sufficient to support a broader indication.
Label breadth will directly influence commercial value, payer negotiations and the number of eligible treatment centres. It will also affect how physicians combine deramiocel with steroids, gene therapies, exon-skipping medicines and other treatments.
Why does Capricor’s dispute with Nippon Shinyaku create a separate risk even if deramiocel is approved?
Capricor entered an agreement in 2022 granting Nippon Shinyaku and its United States subsidiary, NS Pharma, exclusive American distribution rights for deramiocel.
In May 2026, Capricor filed legal action seeking to rescind the agreement. The company alleged that the pricing formula had become commercially unworkable under the Medicare reimbursement system and that the distributor had failed to prepare adequately for launch.
Nippon Shinyaku and NS Pharma have the opportunity to dispute those allegations, and the litigation remains separate from the FDA review.
The conflict creates uncertainty around who will distribute deramiocel if approval is granted, how the product will be priced and whether hospitals will receive adequate reimbursement for acquiring, storing and administering it.
Cell therapies can be financially difficult for treatment centres when reimbursement arrives after the hospital has already paid for the product. A distribution structure that leaves providers exposed to losses could restrict patient access despite regulatory approval.
Capricor says it is preparing for launch independently and has argued that the FDA timeline remains unaffected. The company nevertheless needs a legally and operationally clear distribution pathway before August.
Approval without launch readiness could delay revenue and frustrate families expecting rapid access.
Does Capricor have enough cash and manufacturing capacity to commercialise deramiocel?
Capricor reported approximately $279 million in cash and investments at the end of the first quarter of 2026. The company expects the balance to support operations into the fourth quarter of 2027.
That runway gives Capricor greater flexibility than many small biotechnology companies approaching their first potential approval.
The company is expanding its manufacturing facility, building commercial capabilities and recruiting executives with Duchenne launch experience.
Approval may also make Capricor eligible for a rare pediatric disease Priority Review Voucher. Such vouchers are transferable and have historically been sold by biotechnology companies to generate non-dilutive capital.
The balance sheet does not eliminate commercial risk. Building inventory, patient-support services, payer infrastructure, medical affairs and distribution can consume capital quickly.
The dispute with Nippon Shinyaku may also require Capricor to assume responsibilities that it previously expected its partner to perform.
Investors will therefore examine whether the existing cash is sufficient not only to launch deramiocel but also to fund post-marketing commitments and continue developing the StealthX exosome platform.
What does the sharp Capricor share-price reaction reveal about investor expectations?
Capricor Therapeutics shares traded near $26.50 on June 26, falling approximately 13% during the session after the advisory committee was announced.
The stock was down roughly 7% from its June 18 close and approximately 10% compared with May 26. It remained within a wide 52-week range of $4.30 to $40.37.
The negative reaction does not necessarily mean investors expect rejection. Advisory committee meetings introduce another binary event, and the public briefing documents may expose regulatory concerns before the final decision.
Some shareholders may also have expected the FDA to complete the review without convening external experts, particularly after the successful HOPE-3 trial.
The stock remains several times above its 52-week low, reflecting the substantial revaluation that followed the Phase 3 success. It is also about one-third below the 52-week high reached when the positive results were first announced.
Sentiment therefore appears cautiously constructive rather than uniformly bullish. The market recognises that HOPE-3 materially strengthened the application but is unwilling to assume that approval, label breadth and commercial execution are guaranteed.
What questions are likely to dominate the July 29 FDA panel discussion?
The first question will be whether the 54% slowing of upper-limb deterioration represents a clinically meaningful benefit across the study population.
Panel members are likely to examine the absolute difference between the treatment groups, the distribution of individual responses and whether certain subgroups drove the result.
The second major question will concern the cardiac endpoint. Experts will assess the reliability of the ejection-fraction measurement, the fibrosis findings and whether the observed one-year benefit is likely to change longer-term cardiac outcomes.
The committee may also discuss whether the five-year HOPE-2 extension supports durability despite its small size and reliance on external comparisons.
Safety, repeat dosing and manufacturing consistency will form another layer of review. An allogeneic cell therapy must demonstrate reproducibility across hundreds or thousands of commercial doses.
Finally, the panel may consider unmet need. Duchenne muscular dystrophy remains progressive despite an expanding treatment landscape, while older and non-ambulatory patients have comparatively limited options.
A favourable unmet-need argument cannot replace adequate evidence, but it can influence how regulators weigh uncertainty against the consequences of delaying access.
Has HOPE-3 done enough to turn deramiocel from a rejected therapy into an approvable one?
HOPE-3 has addressed the most important weakness in Capricor’s earlier application. It provides randomised, placebo-controlled evidence that deramiocel can slow deterioration in both upper-limb and cardiac function.
The results are supported by a smaller Phase 2 study and a five-year extension suggesting that benefit may persist with continued treatment.
My assessment is that deramiocel now has a materially credible approval case. The consistency across skeletal function, cardiac imaging and long-term follow-up distinguishes the programme from one resting on a single favourable endpoint.
The remaining uncertainty lies in the magnitude and generalisability of the benefit, the interpretation of the cardiac measures, manufacturing consistency and the population that should appear on the label.
Commercialisation creates an additional complication. Capricor could obtain approval while remaining entangled in a distribution dispute that affects pricing and access.
The July 29 panel will therefore evaluate more than whether deramiocel produced statistically positive results. It will determine whether repeated donor-derived cell therapy has generated sufficient evidence to become a practical disease-modifying option for patients living with Duchenne muscular dystrophy.
Key takeaways from Capricor’s deramiocel FDA advisory committee
- The FDA will convene its Cellular, Tissue, and Gene Therapies Advisory Committee on July 29, 2026, to review deramiocel ahead of the August 22 target decision date.
- The therapy was rejected in July 2025 after the FDA concluded that the earlier evidence did not establish effectiveness and did not complete its review of parts of the manufacturing package.
- The resubmission includes HOPE-3, a 106-patient randomised Phase 3 trial in which deramiocel slowed upper-limb decline by approximately 54% and cardiac deterioration by approximately 91% relative to placebo.
- Five-year open-label data from nine continuing patients suggest durable upper-limb and cardiac preservation, but the small cohort and external comparisons limit the strength of those findings.
- Approval prospects now appear stronger, while label breadth, manufacturing, repeat-dose safety and the unresolved United States distribution dispute remain material risks.
